Buprenorphine - Hikma Pharmaceuticals USA Inc.

Manufacturer
Hikma Pharmaceuticals USA Inc.
Effective date
2025-02-21
Label type
RISK EVALUATION & MITIGATION STRATEGIES
Version
6
Source
full-release
Hydrated at
2026-06-04 22:50:42

Label at a glance#

ProductBuprenorphine
Label structure7 sections

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

This REMS applies to BTODs indicated for the treatment of opioid dependence. This REMS does not apply to buprenorphine-containing products that are dispensed to patients undergoing treatment through an Opioid Treatment Program under 42 CFR Part 8.

I. Administrative Information

REMS Administrative Information

Risk: accidental overdose, misuse, and abuse

Initial Shared System REMS Approval: 02/2013

Most Recent REMS Update: 02/2025

II. REMS Goals

REMS Goals

The goals of the BTOD REMS are to:

  • Mitigate the risks of accidental overdose, misuse, and abuse
  • Inform prescribers, pharmacists, and patients of the serious risks associated with BTODs

III. REMS Requirements

REMS Requirements

REMS Participant Requirements

BTOD Applicants must ensure that prescribers and patients comply with the following requirements:

1. Prescribers who prescribe or dispense BTODs must:

REMS Participant Requirements

Before treatment initiation (first dose)

  1. Assess the patient’s condition to verify the patient meets the diagnostic criteria for opioid dependence.
  2. Counsel the patient on the risks described in the Prescribing Information and Medication Guide.
  3. Counsel the patient on safe storage of the medication.

During treatment; at the first visit following induction

  1. Prescribe a limited amount of medication.

During treatment; at visits scheduled at intervals commensurate with patient stability

  1. Assess the patient’s compliance with the prescribed medication, appropriateness of the dosage prescribed, whether patient is receiving psychosocial support, and whether patient is making adequate progress towards treatment goals.
  2. Counsel the patient about compliance with their medication.
  3. Complete the Appropriate Use Checklist. Retain a completed copy in the patient’s record or by using another method (e.g. electronic health record) specific to the prescriber’s office practice.
2. Patients who are prescribed BTODs:

REMS Participant Requirements

Before treatment initiation

  1. Receive counseling from the prescriber on the risks and safe storage of the medication.

During treatment; at time intervals determined by your prescriber

  1. Be monitored for compliance with the prescribed medication, appropriateness of the dosage prescribed, assessment of whether receiving psychosocial support, and whether making adequate progress towards treatment goals.

REMS Applicant Requirements

To inform healthcare providers about the REMS and the risks and safe use of BTODs, BTOD Applicants must disseminate REMS communication materials according to the table below:

Target Audience

Communication Materials & Dissemination Plan

All healthcare providers who prescribe BTODs for the treatment of opioid dependence

REMS Letter: Dear Prescriber Letter with attachments, Important Drug Safety Information for Prescribers and Appropriate Use Checklist.

  1. Mail or email within 60 days of approval of the BTOD REMS and annually thereafter.

All new healthcare providers who prescribe BTODs for the treatment of opioid dependence since the last dissemination

REMS Letter: Dear Prescriber Letter with attachments, Important Drug Safety Information for Prescribers and Appropriate Use Checklist

  1. Mail or email monthly.

All retail pharmacies authorized by the DEA to handle schedule III controlled substances

REMS Letter: Dear Pharmacist Letter with attachment, Important Drug Safety Information for Pharmacists.

  1. Mail or email within 60 days of approval of the BTOD REMS and annually thereafter.

To support REMS operations, BTOD Applicants must:

  1. Establish and maintain a REMS website, www.btodrems.com. The REMS website must include the option to print the Prescribing Information, Medication Guides, and REMS materials. All product websites for consumers and healthcare providers must include prominent REMS-specific links to the REMS website. The REMS website must not link back to the promotional product websites.
  2. Make the REMS website fully operational and all REMS materials available through the website, BTOD REMS specialists, and call center within 60 calendar days of REMS modification.
  3. Establish and maintain a REMS call center at 1-855-223-3922.
  4. Ensure that the Medication Guide is made available for dispensing with each BTOD prescription.

To ensure REMS participants’ compliance with the REMS, BTOD Applicants must:

  1. Maintain adequate records to demonstrate that REMS requirements have been met, including, but not limited to, records of mailings and outbound calls. These records must be readily available for FDA inspections.
  2. Establish and maintain a plan for addressing noncompliance with REMS requirements.
  3. Monitor compliance with the prescriber requirements to document prescribing and dispensing with documentation of safe use conditions through surveys of patients and prescribers, evaluations of health care utilization databases, and ongoing surveillance (sources including, but not limited to, internet, national databases, and surveys conducted at substance abuse treatment programs).
  4. On a monthly basis, identify and attempt to contact a random sample of prescribers who were sent educational materials via email or mail during the previous month to create awareness of the REMS, confirm that REMS materials have been received, and confirm understanding of the BTOD REMS requirements.
  5. Provide a copy of the REMS materials to prescribers who request or did not receive the REMS materials.
    1. Provide additional follow-up information about the BTOD REMS.
      1. Option I: a live online meeting to review BTOD REMS requirements
      2. Option II: a field visit to review BTOD REMS requirements
  6. Take reasonable steps to improve operations of and compliance with the requirements in the BTOD REMS based on monitoring and evaluation of the BTOD REMS.

IV. REMS Assessment Timetable

REMS Timetable for Submission Assessments

BTOD NDA Applicants must submit REMS Assessments at 12 months from August 30, 2021, and annually thereafter. To facilitate inclusion of as much information as possible while allowing reasonable time to prepare the submission, the reporting interval covered by each assessment should conclude no earlier than 60 calendar days before the submission date for that assessment. BTOD NDA Applicants must submit each assessment so that it will be received by the FDA on or before the due date.

V. REMS Materials

REMS Material

The following materials are part of the BTOD REMS:

Training and Education Materials

Patient

  1. Medication Guide (available at btodrems.com)

Patient Care Form

  1. Appropriate Use Checklist

Communication Materials

  1. Dear Prescriber Letter
  2. Dear Pharmacist Letter
  3. Important Drug Safety Information for Prescribers
  4. Important Drug Safety Information for Pharmacists

Other Materials

  1. BTOD REMS Website (www.btodrems.com)

VI. Statutory Elements

REMS Elements

This REMS is required under section 505-1 of the Federal Food, Drug and Cosmetic Act (FD&C Act) (21-U.S.C. 355-1) and consists of the following elements:

  1. Medication Guide
  2. Elements to Assure Safe Use:
    1. BTODs are dispensed to patients with evidence or other documentation of safe-use conditions under 505-1(f)(3)(D).
    2. All patients using BTODs are subject to certain monitoring under 505-1(f)(3)(E).
  3. Implementation System
  4. Timetable for Submission of Assessments

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
68654759-f50b-79ef-24c5-544d94fe7d87Product name320251114
08a295bb-88df-4ab0-a120-a75a789a74f1Product name120231013
ab841ac7-728a-4fc9-be0a-35b96cecbf39Product name420230306
100316cc-94a9-474e-97ad-9b5c6ddec605Product name520230125
539bc5d3-546b-4af6-9c31-058ce6c459d3Product name220220210
b871fccd-1de6-4c7f-b9e5-045304641ee6Product name820220118
31e16ab2-c562-4617-a3e8-ed285320e16eProduct name120180201
4c23a34c-e8fc-424c-8fa0-ee064ba6eaefProduct name120170706
a5920611-4285-f024-69b9-39ff338b81eaProduct name520170609
3df867ed-9d48-45cf-bded-1394beaea0b1Product name320161206
973da5bf-b1f9-4de0-81ee-7ca066c98ca4Product name120160712

DailyMed REMS / Drug Safety Documents#

Labels related to this REMS document

DailyMed label, Relation, Version table
DailyMed labelRelationVersionEffectiveManufacturerSource
These highlights do not include all the information needed to use BUPRENORPHINE and NALOXONE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for BUPRENORPHINE and NALOXONE SUBLINGUAL TABLETS. BUPRENORPHINE and NALOXONE sublingual tablets, for sublingual administration CIII Initial U.S. Approval: 2002SPL related document2026-07-26Hikma Pharmaceuticals USA Inc. | West-Ward Columbus Inc.20250925_3cbbd1f7-d478-400b-854c-fbb927aef17a.zip!8b59af6b-236f-4439-b408-cbf433689070.xml
These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS . BUPRENORPHINE AND NALOXONE sublingual tablets, for sublingual administration, CIII Initial U.S. Approval: 2002SPL related document2026-06-10SpecGx LLC20250925_3cbbd1f7-d478-400b-854c-fbb927aef17a.zip!8b59af6b-236f-4439-b408-cbf433689070.xml
These highlights do not include all the information needed to use BUPRENORPHINE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for BUPRENORPHINE SUBLINGUAL TABLETS. BUPRENORPHINE s ublingual t ablets, CIII Initial U.S. Approval: 1981SPL related document2026-05-25Actavis Pharma, Inc.20250925_3cbbd1f7-d478-400b-854c-fbb927aef17a.zip!8b59af6b-236f-4439-b408-cbf433689070.xml
These highlights do not include all the information needed to use BUPRENORPHINE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for BUPRENORPHINE SUBLINGUAL TABLETS. BUPRENORPHINE sublingual tablets, CIII Initial U.S. Approval: 1981SPL related document2026-05-04Rhodes Pharmaceuticals LLC | Knoa Pharmaceuticals LLC20250925_3cbbd1f7-d478-400b-854c-fbb927aef17a.zip!8b59af6b-236f-4439-b408-cbf433689070.xml
These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE sublingual tablets, USP safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE sublingual tablets, USP. BUPRENORPHINE and NALOXONE sublingual tablets, USP, CIII Initial U.S. Approval: 2002SPL related document2026-05-01Rhodes Pharmaceuticals LLC | Knoa Pharmaceuticals LLC | Halo Pharmaceutical Inc.20250925_3cbbd1f7-d478-400b-854c-fbb927aef17a.zip!8b59af6b-236f-4439-b408-cbf433689070.xml
These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS. BUPRENORPHINE AND NALOXONE Sublingual Tablets for sublingual administration CIII Initial U.S. Approval: 2002SPL related document2026-02-28PAI Holdings, LLC dba PAI Pharma20250925_3cbbd1f7-d478-400b-854c-fbb927aef17a.zip!8b59af6b-236f-4439-b408-cbf433689070.xml
These highlights do not include all the information needed to use BUPRENORPHINE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for BUPRENORPHINE SUBLINGUAL TABLETS. BUPRENORPHINE Sublingual Tablets, for sublingual administration CIII Initial U.S. Approval: 2002SPL related document2026-02-28PAI Holdings, LLC dba PAI Pharma20250925_3cbbd1f7-d478-400b-854c-fbb927aef17a.zip!8b59af6b-236f-4439-b408-cbf433689070.xml
These highlights do not include all the information needed to use BUPRENORPHINE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for BUPRENORPHINE SUBLINGUAL TABLETS. BUPRENORPHINE sublingual tablets, for sublingual administration CIII Initial U.S. Approval: 1981SPL related document2026-02-11Sun Pharmaceutical Industries, Inc. | Sun Pharmaceutical Industries Limited20250925_3cbbd1f7-d478-400b-854c-fbb927aef17a.zip!8b59af6b-236f-4439-b408-cbf433689070.xml
These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS. BUPRENORPHINE and NALOXONE sublingual tablets, for sublingual administration CIII Initial U.S. Approval: 2002SPL related document2026-02-10Sun Pharmaceutical Industries, Inc. | Sun Pharmaceutical Industries Limited20250925_3cbbd1f7-d478-400b-854c-fbb927aef17a.zip!8b59af6b-236f-4439-b408-cbf433689070.xml
These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS. BUPRENORPHINE and NALOXONE s ublingual t ablets, CIII Initial U.S. Approval: 2002SPL related document2026-02-06Actavis Pharma, Inc.20250925_3cbbd1f7-d478-400b-854c-fbb927aef17a.zip!8b59af6b-236f-4439-b408-cbf433689070.xml
These highlights do not include all the information needed to use B UPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for B UPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS. BUPRENORPHINE AND NALOXONE sublingual tablets, for sublingual administration CIII Initial U.S. Approval: 2002SPL related document2026-02-02Amneal Pharmaceuticals LLC20250925_3cbbd1f7-d478-400b-854c-fbb927aef17a.zip!8b59af6b-236f-4439-b408-cbf433689070.xml
These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS. BUPRENORPHINE and NALOXONE sublingual tablets, CIII Initial U.S. Approval: 2002SPL related document2026-01-28Lannett Company, Inc.20250925_3cbbd1f7-d478-400b-854c-fbb927aef17a.zip!8b59af6b-236f-4439-b408-cbf433689070.xml
These highlights do not include all the information needed to use BUPRENORPHINE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for BUPRENORPHINE SUBLINGUAL TABLETS. BUPRENORPHINE sublingual tablets, for sublingual administration CIII Initial U.S. Approval: 1981SPL related document2026-01-24Hikma Pharmaceuticals USA Inc. | West-Ward Columbus Inc.20250925_3cbbd1f7-d478-400b-854c-fbb927aef17a.zip!8b59af6b-236f-4439-b408-cbf433689070.xml
These highlights do not include all the information needed to use BUBRENORPHINE AND NALOXONE SUBLINGUAL FILM safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE SUBLINGUAL FILM. BUPRENORPHINE and NALOXONE sublingual film, for sublingual or buccal use CIII Initial U.S. Approval: 2002SPL related document2026-01-15Mylan Pharmaceuticals Inc.20250925_3cbbd1f7-d478-400b-854c-fbb927aef17a.zip!8b59af6b-236f-4439-b408-cbf433689070.xml
These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE SUBLINGUAL FILM safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE SUBLINGUAL FILM. BUPRENORPHINE and NALOXONE sublingual film, for sublingual or buccal use CIII Initial U.S. Approval: 2002SPL related document2026-01-12Dr.Reddys Laboratories Inc | LTS Lohmann Therapy Systems Corp. | Pharmaron Manufacturing services (UK) LTD20250925_3cbbd1f7-d478-400b-854c-fbb927aef17a.zip!8b59af6b-236f-4439-b408-cbf433689070.xml
These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE SUBLINGUAL FILM safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE SUBLINGUAL FILM. BUPRENORPHINE and NALOXONE sublingual film, for sublingual or buccal use CIII Initial U.S. Approval: 2002SPL related document2026-01-12Dr.Reddys Laboratories Inc | LTS Lohmann Therapy Systems Corp. | Pharmaron Manufacturing services (UK) LTD20250925_3cbbd1f7-d478-400b-854c-fbb927aef17a.zip!8b59af6b-236f-4439-b408-cbf433689070.xml
Buprenorphine and Naloxone Sublingual Tablets CIII Rx Only These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for B UPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS. BUPRENORPHINE AND NALOXONE sublingual tablets, for sublingual administration CIII Initial U.S. Approval: 2002SPL related document2026-01-08AvPAK20250925_3cbbd1f7-d478-400b-854c-fbb927aef17a.zip!8b59af6b-236f-4439-b408-cbf433689070.xml
These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE SUBLINGUAL FILM safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE SUBLINGUAL FILM. BUPRENORPHINE and NALOXONE sublingual film, for sublingual or buccal use, CIII Initial U.S. Approval: 2002SPL related document2026-01-01Alvogen Inc.20250925_3cbbd1f7-d478-400b-854c-fbb927aef17a.zip!8b59af6b-236f-4439-b408-cbf433689070.xml
These highlights do not include all the information needed to use ZUBSOLV ® safely and effectively. See full prescribing information for ZUBSOLV. ZUBSOLV (buprenorphine and naloxone sublingual tablets), CIII Initial U.S. Approval: 2002SPL related document2025-12-27Orexo US, Inc.20250925_3cbbd1f7-d478-400b-854c-fbb927aef17a.zip!8b59af6b-236f-4439-b408-cbf433689070.xml
These highlights do not include all the information needed to use SUBOXONE sublingual film safely and effectively. See full prescribing information for SUBOXONE sublingual film. SUBOXONE ® (buprenorphine and naloxone) sublingual film, for sublingual or buccal use, CIII Initial U.S. Approval: 2002SPL related document2025-12-22INDIVIOR INC. | Alcami Carolinas Corporation | Aquestive Therapeutics | Butterworth Laboratories Ltd | INDIVIOR UK Limited | Infinity Labs IN, Inc | Macfarlan Smith Limited | PPD Development, L.P. | QUOTIENT SCIENCES (ALNWICK) LIMITED | SGS North America Inc. | Sharp Packaging Services, LLC | Siegfried AG | SpecGx LLC | Veranova, L.P.20250925_3cbbd1f7-d478-400b-854c-fbb927aef17a.zip!8b59af6b-236f-4439-b408-cbf433689070.xml
These highlights do not include all the information needed to use BUPRENORPHINE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for BUPRENORPHINE SUBLINGUAL TABLETS. BUPRENORPHINE sublingual tablets, CIII Initial U.S. Approval: 1981SPL related document2024-12-30American Health Packaging20250925_3cbbd1f7-d478-400b-854c-fbb927aef17a.zip!8b59af6b-236f-4439-b408-cbf433689070.xml
BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS. These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS. BUPRENORPHINE AND NALOXONE Sublingual Tablets for sublingual administration CIII Initial U.S. Approval: 2002SPL related document2023-08-10Golden State Medical Supply, Inc. | Ethypharm USA Corp. | Ethypharm20250925_3cbbd1f7-d478-400b-854c-fbb927aef17a.zip!8b59af6b-236f-4439-b408-cbf433689070.xml
These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE SUBLINGUAL FILM safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE SUBLINGUAL FILM. BUPRENORPHINE and NALOXONE sublingual film, for sublingual or buccal use CIII Initial U.S. Approval: 2002SPL related document2023-07-06Apotex Corp. | Aveva Drug Delivery Systems, Inc. | Aveva Drug Delivery Systems, Inc20250925_3cbbd1f7-d478-400b-854c-fbb927aef17a.zip!8b59af6b-236f-4439-b408-cbf433689070.xml
These highlights do not include all the information needed to use BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS safely and effectively. See full prescribing information for BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS. BUPRENORPHINE and NALOXONE sublingual tablets, for sublingual administration CIII Initial U.S. Approval: 2002SPL related document2023-05-03Accord Healthcare, Inc | WES PHARMA INC20250925_3cbbd1f7-d478-400b-854c-fbb927aef17a.zip!8b59af6b-236f-4439-b408-cbf433689070.xml

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 29 matching rows.

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 2 · 27 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
BuprenorphineBUPRENORPHINEREMEDYREPACK INC.aa86a438-1ebf-4c08-bf27-38f1e81efb3a2026-07-07Warnings, Adverse reactionsName fallback
brand name: Buprenorphine
BUPRENORPHINEBUPRENORPHINEUnit Dose Solutions, Inc.5578cd5c-c860-6e8a-e063-6394a90a56c72026-06-30Warnings, Adverse reactionsName fallback
brand name: BUPRENORPHINE
BUPRENORPHINEBUPRENORPHINEBryant Ranch Prepackaa132031-9d12-45b4-81e0-4a58776613792026-06-29Warnings, Adverse reactionsName fallback
brand name: BUPRENORPHINE
BuprenorphineBUPRENORPHINEBryant Ranch Prepack655e3e52-03be-496c-978a-5cffc74b2ae42026-06-29Warnings, Adverse reactionsName fallback
brand name: Buprenorphine
BUPRENORPHINEBUPRENORPHINEUnit Dose Solutions, Inc.5479b218-a388-2c3c-e063-6294a90a0e852026-06-17Warnings, Adverse reactionsName fallback
brand name: BUPRENORPHINE
BUPRENORPHINEBUPRENORPHINEBryant Ranch Prepack966adb01-71b4-4e0b-bbc6-b83da9987aa22026-06-16Warnings, Adverse reactionsName fallback
brand name: BUPRENORPHINE
BuprenorphineBUPRENORPHINEMajor Pharmaceuticalsdba586f9-e3f2-4b9c-849b-907c81a5a0ef2026-06-16Warnings, Adverse reactionsName fallback
brand name: Buprenorphine
BUPRENORPHINEBUPRENORPHINEBryant Ranch Prepackbc5a7137-9e8f-438e-84d9-bdbf1db129982026-06-03Warnings, Adverse reactionsName fallback
brand name: BUPRENORPHINE
BuprenorphineBUPRENORPHINERhodes Pharmaceuticals LLC2738feae-316e-426f-971c-5f142ac01b602026-05-29Boxed warning, Warnings, Adverse reactionsName fallback
brand name: Buprenorphine
BuprenorphineBUPRENORPHINEActavis Pharma, Inc.03819118-86f6-4329-adaf-4599e7b71f462026-05-25Warnings, Adverse reactionsName fallback
brand name: Buprenorphine
BuprenorphineBUPRENORPHINETeva Pharmaceuticals USA, Inc.36995ce3-b515-447b-baa9-aa14f84060d82026-05-12Boxed warning, Warnings, Adverse reactionsName fallback
brand name: Buprenorphine
BUPRENORPHINEBUPRENORPHINERhodes Pharmaceuticals LLCda90618a-5621-4b15-bc48-9dcc631418de2026-05-04Warnings, Adverse reactionsName fallback
brand name: BUPRENORPHINE
BuprenorphineBUPRENORPHINEINGENUS PHARMACEUTICALS, LLC186e3be6-8bc0-4bb9-96f5-429d53632f452026-04-28Boxed warning, Warnings, Adverse reactionsName fallback
brand name: Buprenorphine
BuprenorphineBUPRENORPHINEAveva Drug Delivery Systems Inc.1aae9b13-7431-42ef-8558-14a2325820e62026-04-28Boxed warning, Warnings, Adverse reactionsName fallback
brand name: Buprenorphine
BUPRENORPHINEBUPRENORPHINEBryant Ranch Prepackcd0a90c6-32cc-4114-8573-86ac85503bdf2026-04-03Warnings, Adverse reactionsName fallback
brand name: BUPRENORPHINE
BuprenorphineBUPRENORPHINESun Pharmaceutical Industries, Inc.9fd1f18f-0b0f-4059-b603-19ecbf0ed63a2026-02-11Warnings, Adverse reactionsName fallback
brand name: Buprenorphine
BUPRENORPHINEBUPRENORPHINEA-S Medication Solutionsbfb02ea5-22f2-432e-afc8-f1dbe2ea06142026-02-06Warnings, Adverse reactionsName fallback
brand name: BUPRENORPHINE
BuprenorphineBUPRENORPHINEHikma Pharmaceuticals USA Inc.1bf8b35a-b769-465c-a2f8-099868dfcd2f2026-01-24Warnings, Adverse reactionsName fallback
brand name: Buprenorphine
BuprenorphineBUPRENORPHINEAmneal Pharmaceuticals NY LLCc7d079fb-507f-436f-b794-2171b7d970672026-01-09Boxed warning, Warnings, Adverse reactionsName fallback
brand name: Buprenorphine
BuprenorphineBUPRENORPHINEAvPAK1408cd8f-a0b5-6be7-e063-6394a90a0b412026-01-08Warnings, Adverse reactionsName fallback
brand name: Buprenorphine

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.